CD-MEDICS

The overall concept of the CD-MEDICS IP is to develop a technology platform for point-of-care diagnostics, capable of simultaneous genomic and proteomic detection, with embedded communication abilities for direct interfacing with hospital information systems. This will be achieved by exploiting breakthroughs at the confluences of bio-, micro- and nano- technologies to create a low-cost non-invasive intelligent diagnosis system.

This platform will be developed in a modular format, which will allow each module to be developed and exploited individually. The modules will subsequently be integrated to facilitate the desired application. Advances in data communications, molecular biology and biosensor technology, with the integration of nanostructured functional components in macro and microsystems, will facilitate the realisation of a minimally invasive generic platform, which is capable of multi-parametric monitoring and will be interoperable with electronic medical records.

The advantages of integrated biosensor systems include their ease of use, their sensitivity, their inherent selectivity (preventing problems due to interfering substances), their versatility (allowing `in-field¿ use) and their cost effectiveness. Addressing the future health care requirement of an individualised theranostic approach, the specific application that will be demonstrated in this IP will be for the management, monitoring and diagnosis of coeliac disease, with the proposed technology contributing to significant advances in sensitivity and specificity of diagnosis. The technology platform developed, however, could be applied to a variety of clinical screening applications, such as cancer. The radical innovation proposed in this IP will result in a concrete prime deliverable of a technology platform of wide application and unquestionable socio-economic benefit, increasing European competitiveness whilst contributing considerably to the quality of life well being of the population.

For further information, please visit:
http://www.cdmedics.eu

Project co-ordinator:
Universitat Rovira i Virgili

Partners:

  • Institut für Mikrotechnik Mainz GmbH
  • Microfluidic ChipShop GmbH
  • Newcastle University
  • Intracom Telecom solutions
  • Clemens GmbH
  • Micro2Gen
  • Eurospital SpA
  • King's College London Business Ltd
  • INNO-TRAIN Diagnostik GmbH
  • TATAA Biocenter
  • MultiD Analyses AB
  • Finnish Red Cross Blood Service
  • Fondazione IRCCS Policlinico San Matteo
  • University Medical Centre Maribor
  • Valentia Technologies Limited
  • Association of European Coeliac Societies
  • Coeliac UK
  • Asociación de celíacos de Madrid
  • iXscient Ltd.
  • Newcastle upon Tyne Hospitals NHS Foundation Trust

Timetable: from 01/2008 – to 12/2011

Total cost: € 12.796.559

EC funding: € 9.500.000

Programme Acronym: FP7-ICT

Subprogramme Area: Personal health systems for monitoring and point-of-care diagnostics

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

NHS and Patients to Benefit from New Par…

IMS MAXIMS and Secure Exchange Solutions have announced a partnership to offer mobile, secure and cost-effective provider-to-provider and provider-to-patient communications to NHS organisations, GP practices and patients.

International Master's in Digital Health

The Master of Science (M.Sc.) in Medical Informatics (MMI) at European Campus Rottal-Inn (ECRI) in Pfarrkirchen - a branch of the Deggendorf University of Applied Sciences (THD - Technische Hochschule...

Digital Medicine: The Opportunities and …

9 - 11 April 2019, Berlin, Germany. Be it preventive healthcare for dementia using intuitive apps, anonymous hospital hygiene inspections using IoT sensors, or VR applications that let hemiplegic patients live...

Highland Marketing Forms Alliance with E…

An alliance between Highland Marketing and Experiential HealthTech will be announced at this year's Digital Health Rewired, with both companies exhibiting from stand B14. Highland Marketing is a full-service marketing...

Google Research Shows How AI can Make Op…

As artificial intelligence continues to evolve, diagnosing disease faster and potentially with greater accuracy than physicians, some have suggested that technology may soon replace tasks that physicians currently perform. But...

Virtual Reality could be Used to Treat A…

Playing games in virtual reality (VR) could be a key tool in treating people with neurological disorders such as autism, schizophrenia and Parkinson's disease. The technology, according to a recent...

Open Call SC1-HCC-02-2019: Support for t…

In the past years several open service platforms for Active and Healthy Ageing domains have been developed, originating from the medical, independent living, and IoT domain. These platforms aim at...

Have an Innovative Digital Health Soluti…

G4A Partnerships are a great opportunity to get your solution in front of Bayer executives and decision makers. All the applications will be reviewed by key stakeholders who have global...

The Moore Blatch Silicon Cup Opens for E…

This year's Moore Blatch Silicon Cup has been launched and is now open for IT companies to enter. The event takes place over 26 - 27 September on the Isle...

MEDICA 2019: Clear Focus on Future Topic…

18 - 21 November 2019, Düsseldorf, Germany. As a result of the final phase of exhibitor registrations for the world’s leading medical trade fare MEDICA 2019 in Düsseldorf, one thing is...

Artificial Intelligence Sheds New Light …

What happens inside a cell when it is activated, changing, or responding to variations in its environment? Researchers from the VIB-UGent Center for Inflammation Research have developed a map of...